Nazione: Canada
Lingua: inglese
Fonte: Health Canada
LOVASTATIN
AVANSTRA INC
C10AA02
LOVASTATIN
20MG
TABLET
LOVASTATIN 20MG
ORAL
100
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0120669002; AHFS:
CANCELLED POST MARKET
2014-08-21
_ _ _Sandoz Lovastatin _ _Page 1 of 43_ PRODUCT MONOGRAPH PR AVA- LOVASTATIN Lovastatin Tablets USP 20 mg and 40 mg Lipid Metabolism Regulator . Date of Revision: May 31, 2013 Avanstra Inc 10761 – 25th Street NE, Suite 110 Calgary, Alberta, Canada, T3N 0A4 Submission Control Number: 163752 _ _ _Sandoz Lovastatin _ _Page 2 of 43_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................12 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................17 OVERDOSAGE ................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................19 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................20 PART II: SCIENTIFIC INFORMATION ...............................................................................21 PHARMACEUTICAL INFORMATION ..........................................................................21 CLINICAL TRIALS ..........................................................................................................22 DETAILED PHARMACOLOGY ........................ Leggi il documento completo